Taysha Gene Therapies (TSHA) News Today $1.61 -0.03 (-1.83%) Closing price 04:00 PM EasternExtended Trading$1.63 +0.02 (+1.49%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Taysha Gene Therapies (TSHA) Projected to Post Earnings on WednesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings before the market opens on Wednesday, February 26, Financial Modeling Prep reports.February 21 at 2:06 AM | marketbeat.comTaysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26February 19 at 8:00 AM | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from BrokeragesFebruary 19 at 2:55 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3% - Time to Buy?Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 1.3% - Time to Buy?February 15, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have received a consensus recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 yeaFebruary 14, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) & Creative Medical Technology (NASDAQ:CELZ) Critical SurveyFebruary 14, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comTaysha Gene Therapies Is Showing Promise For Rett SyndromeJanuary 27, 2025 | seekingalpha.comEquities Analysts Set Expectations for TSHA FY2025 EarningsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Taysha Gene Therapies in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earniJanuary 22, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by AnalystsTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month target price among brJanuary 20, 2025 | marketbeat.comBarclays PLC Increases Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Barclays PLC boosted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 356.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 247,280 shares of the company's stock after purchasing an additional 193,046 sharJanuary 18, 2025 | marketbeat.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Monday.January 6, 2025 | marketbeat.comTaysha Gene Therapies announces inducement grant under Nasdaq listing ruleJanuary 3, 2025 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comGeode Capital Management LLC Acquires 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,562,758 shaJanuary 3, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest UpdateTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 21,880,000 shares, an increase of 39.6% from the November 30th total of 15,670,000 shares. Based on an average trading volume of 4,270,000 shares, the short-interest ratio is currently 5.1 days.December 28, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesTaysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average recommendation of "Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year target price among broDecember 26, 2024 | marketbeat.comWellington Management Group LLP Purchases Shares of 463,192 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Wellington Management Group LLP acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 463,192 shares of the company's stock, valued at apprDecember 20, 2024 | marketbeat.comTaysha Gene Therapies files for $300M mixed shelf offeringDecember 14, 2024 | msn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Fmr LLCFmr LLC reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,678,527 shares of the company's stock aDecember 9, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading 6.3% Higher - Should You Buy?Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.3% - Time to Buy?December 6, 2024 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comRTW Investments LP Sells 3,853,879 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)RTW Investments LP cut its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 20.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,946,420 shares of the company's stock afteDecember 5, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-yearDecember 1, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3% - Still a Buy?Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3% - What's Next?November 29, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) is Acuta Capital Partners LLC's 10th Largest PositionAcuta Capital Partners LLC reduced its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 9.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,118,992 shares of the company's stockNovember 28, 2024 | marketbeat.comTaysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome marketNovember 27, 2024 | uk.investing.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8% - Here's What HappenedTaysha Gene Therapies (NASDAQ:TSHA) Trading 13.8% Higher - Should You Buy?November 22, 2024 | marketbeat.comBuy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral DoseNovember 21, 2024 | markets.businessinsider.comCanaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceCanaccord Genuity Group raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday.November 15, 2024 | marketbeat.comQ3 2024 Taysha Gene Therapies Inc Earnings CallNovember 14, 2024 | finance.yahoo.comTaysha Gene Therapies: Promising Progress and Financial Stability Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comBuy Rating Justified for Taysha Gene Therapies Amid Promising TSHA-102 Developments and Upcoming CatalystsNovember 14, 2024 | markets.businessinsider.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - What's Next?Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - What's Next?November 14, 2024 | marketbeat.comTaysha Gene Therapies: Promising Developments and Strong Financial Position Support Buy RatingNovember 14, 2024 | markets.businessinsider.comNeurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" (TSHA)Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.November 14, 2024 | marketbeat.comTaysha Gene Therapies Advances in Rett Syndrome TrialsNovember 14, 2024 | markets.businessinsider.comTaysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comTaysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comPositive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over NeurogeneNovember 13, 2024 | markets.businessinsider.comPiper Sandler Releases a Buy Rating on Taysha Gene Therapies (TSHA)November 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Promising TSHA-102 Trial ResultsNovember 13, 2024 | markets.businessinsider.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday.November 12, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday.November 12, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday.November 12, 2024 | marketbeat.comTaysha Gene Therapies (TSHA) Scheduled to Post Quarterly Earnings on WednesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comTaysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13November 6, 2024 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from AnalystsShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year targetNovember 6, 2024 | marketbeat.comOptimistic Buy Rating for Taysha Gene Therapies Amid Promising Rett Syndrome Study OutcomesNovember 5, 2024 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.com Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Media Mentions By Week TSHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼0.410.60▲Average Medical News Sentiment TSHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼43▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News VIR News SNDX News ARVN News ANIP News DAWN News ADPT News RCUS News CALT News SYRE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSHA Stock Alerts